4D Molecular director granted 75,000 stock options
4D Molecular Therapeutics director John F. Milligan received a grant of stock options covering 75,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
4D Molecular Therapeutics director John F. Milligan received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $9.42 per share and were automatically granted under the non-employee director compensation program. One-third vests on June 17, 2027, with the rest vesting in equal monthly installments until fully vested on June 17, 2029, or sooner upon a Change in Control, and they expire on June 16, 2036.
Insider Trade Summary
Grant/Award: 75,000 shares
Grant/Award
1 txn
Insider
MILLIGAN JOHN F
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 75,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 75,000 contracts (Direct)
Footnotes (2)
- F1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
- F2. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
Key Figures
Option grant size: 75,000 options
Exercise price: $9.42 per share
Underlying shares: 75,000 shares
+4 more
7 metrics
Option grant size
75,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$9.42 per share
Exercise price for 75,000 stock options
Underlying shares
75,000 shares
Common Stock underlying the option award
Post-grant derivative holdings
75,000 options
Total options held following this transaction
Initial vesting date
June 17, 2027
One-third of options vest on this date
Full vesting date
June 17, 2029
All options fully vested by this date
Expiration date
June 16, 2036
Option term end date
Key Terms
Stock Option (Right to Buy), non-employee director compensation program, Change in Control, 2020 Incentive Award Plan
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
non-employee director compensation program financial
"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."
Change in Control financial
"will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2020 Incentive Award Plan financial
"Change in Control (as defined in the 2020 Incentive Award Plan)."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did 4D Molecular Therapeutics (FDMT) report for John F. Milligan?
4D Molecular Therapeutics reported a grant of stock options to director John F. Milligan for 75,000 shares of common stock at an exercise price of $9.42 per share, issued as part of the company’s non-employee director compensation program.
What are the vesting terms of John F. Milligan’s 75,000 FDMT stock options?
The stock options vest one-third on June 17, 2027, with the remaining two-thirds vesting in equal monthly installments thereafter. Vesting continues until all 75,000 underlying common shares are fully vested on June 17, 2029, assuming Milligan continues serving the company.
When do John F. Milligan’s FDMT stock options expire and what is the exercise price?
The options granted to John F. Milligan carry an exercise price of $9.42 per share and expire on June 16, 2036. They represent rights to buy 75,000 shares of 4D Molecular Therapeutics common stock if exercised before the expiration date.
How were John F. Milligan’s FDMT stock options granted under the company’s compensation program?
The stock options were automatically granted under 4D Molecular Therapeutics’ non-employee director compensation program. This means they were awarded as part of a standard compensation arrangement for directors rather than as a discretionary, one-off award.
What happens to John F. Milligan’s FDMT options upon a Change in Control?
The filing states that Milligan’s stock options will vest in full upon the consummation of a Change in Control, as defined in the 2020 Incentive Award Plan. This accelerates vesting so all 75,000 underlying shares become exercisable at that event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates